Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Objective:  To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment.

[1]  R. Perlis,et al.  Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine , 2006, Journal of clinical psychopharmacology.

[2]  T. Su,et al.  Association of initial antipsychotic response to clozapine and long-term weight gain. , 2006, The American journal of psychiatry.

[3]  J. Prous,et al.  Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. , 2005, Methods and findings in experimental and clinical pharmacology.

[4]  Hui-Ching Liu,et al.  The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naïve Schizophrenic Patients , 2006, Journal of clinical psychopharmacology.

[5]  Irwin Nazareth,et al.  Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. , 2007, Archives of general psychiatry.

[6]  Craig W. Colton,et al.  Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States , 2006, Preventing chronic disease.

[7]  J. Lieberman,et al.  Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 , 2008, Schizophrenia Research.

[8]  Hyunsoon Cho,et al.  Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects , 2008, Schizophrenia Research.

[9]  J. Ananth,et al.  A typical Antipsychotic Induced Weight Gain: Pathophysiology and Management , 2004 .

[10]  S. Stahl.  Neuropharmacology of obesity: my receptors made me eat it. , 1998, The Journal of clinical psychiatry.

[11]  Carmen Moreno,et al.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. , 2006, Archives of general psychiatry.

[12]  S. Stahl,et al.  Dosing Atypical Antipsychotics , 2008, CNS Spectrums.

[13]  J. Wess,et al.  A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. , 2006, Cell metabolism.

[14]  Geoffrey C. Williams,et al.  Prevalence of the metabolic syndrome among patients receiving clozapine. , 2006, The American journal of psychiatry.

[15]  D. Jeste,et al.  Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. , 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[16]  P. Weiden,et al.  Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone , 2008, Neuropsychopharmacology.

[17]  Donald R. Miller,et al.  Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. , 2006, American journal of epidemiology.

[18]  S. Strakowski,et al.  Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. , 2007, Journal of child and adolescent psychopharmacology.

[19]  J. Thakore.  Metabolic syndrome and schizophrenia. , 2005, The British journal of psychiatry : the journal of mental science.

[20]  O. Andreassen,et al.  Dyslipidemia Independent of Body Mass in Antipsychotic-Treated Patients Under Real-Life Conditions , 2008, Journal of clinical psychopharmacology.

[21]  J. Ananth,et al.  Atypical antipsychotic induced weight gain: pathophysiology and management. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[22]  J. Kennedy,et al.  Genetics of antipsychotic treatment emergent weight gain in schizophrenia. , 2006, Pharmacogenomics.

[23]  G. L’italien,et al.  Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. , 2007, The Journal of clinical psychiatry.

[24]  J. Vázquez-Barquero,et al.  Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population , 2008, Schizophrenia Research.

[25]  J. Wess,et al.  Role of the M3 muscarinic acetylcholine receptor in β‐cell function and glucose homeostasis , 2007, Diabetes, obesity & metabolism.

[26]  J. Mintz,et al.  Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia: An Observational Pharmacoepidemiology Study From 1988 to 2002 , 2007, Journal of clinical psychopharmacology.

[27]  J. Meyer.  Novel antipsychotics and severe hyperlipidemia , 2000, Schizophrenia Research.

[28]  M. O’Donovan,et al.  Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? , 2005, Journal of psychopharmacology.

[29]  J. Skala,et al.  Severe mental illness increases the risk of death from coronary heart disease or stroke , 2007, Evidence-based mental health.

[30]  G. L’italien,et al.  Hyperlipidemia following treatment with antipsychotic medications. , 2006, The American journal of psychiatry.

[31]  M. Atmaca,et al.  Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[32]  G. Reynolds,et al.  The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  H. Nasrallah,et al.  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles , 2008, Molecular Psychiatry.

[34]  O. Andreassen,et al.  Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. , 2008, The international journal of neuropsychopharmacology.

[35]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[36]  S. Buchholz,et al.  Atypical antipsychotic‐induced diabetes mellitus: an update on epidemiology and postulated mechanisms , 2008, Internal medicine journal.

[37]  Anne W. Schmidt,et al.  Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. , 2005, Diabetes.

[38]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[39]  W. Fenton,et al.  Medication-induced weight gain and dyslipidemia in patients with schizophrenia. , 2008, The American journal of psychiatry.

[40]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[41]  S. Snyder,et al.  Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase , 2007, Proceedings of the National Academy of Sciences.

[42]  W. Garvey,et al.  Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis , 2007, Neuropsychopharmacology.

[43]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[44]  D. Chisholm,et al.  Abdominal Fat and Insulin Resistance in Normal and Overweight Women: Direct Measurements Reveal a Strong Relationship in Subjects at Both Low and High Risk of NIDDM , 1996, Diabetes.

[45]  K. Houseknecht,et al.  Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects , 2007, Neuropsychopharmacology.

[46]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[47]  M. Keshavan,et al.  Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. , 2006, Journal of clinical psychopharmacology.